Butterfly Network, Inc. filings document the formal disclosures of a public digital health company built around Ultrasound-on-Chip devices, ultrasound software and AI. Recent 8-K reports furnish quarterly and annual results, business updates, material agreements, executive and director matters, and listing-status notices affecting securities issued in connection with its prior business combination with Longview Acquisition Corp.
Proxy materials describe annual meeting proposals, director elections, auditor ratification and executive-compensation votes. Other filings cover the company’s Class A common stock, public warrants, capital structure and governance, including the NYSE Form 25 record for removal of the warrants from listing and registration, while operating disclosures address point-of-care ultrasound and Butterfly Embedded licensing activity.
Butterfly Network, Inc. reported strong fourth quarter 2025 results, highlighted by record quarterly revenue of $31.5 million, up 41% from $22.4 million a year earlier, and its first quarter of positive operating cash flow with net cash inflow of $6.3 million.
U.S. revenue grew to $26.8 million, a 55% increase, helped by $6.8 million from a new Midjourney co-development partnership, while international revenue was $4.7 million. GAAP gross margin improved to 67.3%, driven by high-margin Butterfly Embedded licensing and lower software amortization.
Net loss narrowed to $15.3 million from $18.1 million, and adjusted EBITDA loss improved to $3.2 million from $9.1 million. Cash and cash equivalents reached $150.5 million as of December 31, 2025. For 2026, the company guides to revenue of $117–$121 million, implying about 20–24% growth, and an adjusted EBITDA loss of $21–$25 million.
Butterfly Network, Inc. received an amended Schedule 13D/A from Glenview Capital entities and Larry Robbins updating their ownership and warrant status. Glenview Capital Management, LLC reports beneficial ownership of 14,335,055 shares of Class A common stock, representing 6.34% of the class. Larry Robbins reports beneficial ownership of 19,268,892 shares, or 8.52% of the class, including stock options and unvested restricted stock units tied to his service on the board. The amendment also notes that private placement warrants held by Glenview funds and Longview Investors LLC expired on February 12, 2026, unexercised and for no value.
Butterfly Network, Inc. received an updated ownership report showing that Fosun Industrial Co., Limited and its parent Shanghai Fosun Pharmaceutical (Group) Co., Ltd. together beneficially own 10,716,630 shares of Butterfly’s Class A common stock, representing 4.7% of the class as of December 31, 2025.
The filing states all 10,716,630 shares are held by Fosun Industrial, with both Fosun entities sharing voting and dispositive power. The 4.7% figure is calculated against 226,175,175 Class A shares outstanding as of October 21, 2025, and the investors certify the stake is held on a passive basis, not to influence control.
Butterfly Network, Inc. is having its redeemable warrants removed from listing and registration on the New York Stock Exchange. These securities are redeemable warrants, with each whole warrant exercisable for one share of Class A common stock at an exercise price of $11.50 per share.
The Vanguard Group filed a Schedule 13G reporting a passive ownership stake in Butterfly Network Inc. common stock. Vanguard reports beneficial ownership of 11,315,969 shares, representing 5% of the class as of the event date of 12/31/2025.
Vanguard has shared voting power over 1,457,633 shares and shared dispositive power over 11,315,969 shares, with no sole voting or dispositive power. The filing notes an internal realignment effective January 12, 2026, after which certain Vanguard subsidiaries are expected to report beneficial ownership separately. Vanguard certifies the shares are held in the ordinary course of business and not for the purpose of changing or influencing control of Butterfly Network.
Butterfly Network, Inc. reports that the New York Stock Exchange will delist, and has immediately suspended trading in, its public warrants (ticker BFLY WS) because of “abnormally low selling price” levels under Section 802.01D of the NYSE Listed Company Manual as of January 13, 2026. Each warrant was issued in the February 16, 2021 business combination with Longview Acquisition Corp. and is exercisable for one share of Class A common stock at an exercise price of $11.50 per share until its expiration on February 12, 2026. The company states it does not believe the warrant delisting is related to its performance, and confirms that trading in its Class A common stock, which continues on the NYSE under ticker BFLY, is unaffected.
Butterfly Network, Inc. reported that it has announced preliminary financial results for the fourth quarter ended December 31, 2025. The company made this disclosure through a press release dated January 12, 2026, which is included as Exhibit 99.1 to this report. The Class A common stock trades on the New York Stock Exchange under the symbol BFLY, and its publicly traded warrants trade under BFLY WS. The report is signed on behalf of the company by Chief Financial Officer John Doherty.
Butterfly Network, Inc. executive vice president and chief financial officer John N. Doherty reported an automatic sale of company stock tied to tax withholding. On January 7, 2026, he sold 60,182 shares of Class A common stock at a weighted average price of $3.98 per share, with individual sale prices ranging from $3.915 to $4.055. According to the company’s “sell-to-cover” policy, these sales were made only to cover tax obligations arising from the vesting of restricted stock units and were not at his discretion. After the transaction, Doherty beneficially owned 1,234,688 shares of Butterfly Network Class A common stock.
Butterfly Network, Inc. director and 10% owner Jonathan M. Rothberg reported sales of Class A common stock made indirectly through JAR TR, LLC. JAR TR, LLC sold 351,617 shares on 01/06/2026 at a weighted average price of $4.0294, 452,729 shares on 01/07/2026 at $4.1399, and 335,834 shares on 01/08/2026 at $4.1822, leaving no Class A shares held by that entity after the reported transactions.
The sales were effected under a Rule 10b5-1 trading plan adopted on March 5, 2025 for estate-planning purposes. Rothberg remains associated with substantial holdings of Class A and Class B common stock through direct ownership, his spouse, and multiple LLC and trust entities, while disclaiming beneficial ownership of those securities except to the extent of his pecuniary interest.
Butterfly Network Inc. insider Dr. Jonathan Rothberg has filed a notice to sell 335,834 shares of common stock through broker Jefferies on the NYSE, with an aggregate market value of 1,404,525.00. The filing reports that 226,200,000 shares of common stock are outstanding.
The shares to be sold were originally acquired in a private purchase from Butterfly Network Inc. on 08/31/2014, when 176,070 shares were bought for cash. The notice also lists multiple recent sales by Dr. Rothberg over the past three months, including 1,110,579 shares sold on 11/24/2025 for gross proceeds of 3,503,032.70 and 452,729 shares sold on 01/07/2026 for 1,874,252.00. By signing, the seller represents that he is not aware of undisclosed material adverse information about the company.